Compare RNW & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNW | LQDA |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | N/A | 2018 |
| Metric | RNW | LQDA |
|---|---|---|
| Price | $7.58 | $30.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $7.83 | ★ $37.40 |
| AVG Volume (30 Days) | 1.1M | ★ 2.2M |
| Earning Date | 11-10-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 413.66 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $1,382,164,625.00 | $69,216,000.00 |
| Revenue This Year | N/A | $424.31 |
| Revenue Next Year | $16.58 | $359.32 |
| P/E Ratio | $29.00 | ★ N/A |
| Revenue Growth | 46.76 | ★ 343.41 |
| 52 Week Low | $5.42 | $10.37 |
| 52 Week High | $8.24 | $32.80 |
| Indicator | RNW | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 52.62 | 60.95 |
| Support Level | $7.22 | $27.76 |
| Resistance Level | $7.69 | $32.80 |
| Average True Range (ATR) | 0.11 | 1.78 |
| MACD | 0.03 | 0.20 |
| Stochastic Oscillator | 77.66 | 68.59 |
ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.